 NanoViricides Inc NYSE: NNVC has initiated a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F hAd41-F, believed to be strongly associated with the occurrence of severe hepatitis syndrome in some children. The company says. 